University of Groningen

Pneumococcal conjugate vaccines for preventing otitis media

Jansen, Angelique G S C; Hak, Eelko; Veenhoven, Reinier H; Damoiseaux, Roger A M J; Schilder, Anne G M; Sanders, Elisabeth A M

Published in:
Cochrane database of systematic reviews (Online)

DOI:
[10.1002/14651858.CD001480.pub3](https://doi.org/10.1002/14651858.CD001480.pub3)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2009

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Jansen, A. G. S. C., Hak, E., Veenhoven, R. H., Damoiseaux, R. A. M. J., Schilder, A. G. M., & Sanders, E. A. M. (2009). Pneumococcal conjugate vaccines for preventing otitis media. *Cochrane database of systematic reviews (Online)*, (2), CD001480. <https://doi.org/10.1002/14651858.CD001480.pub3>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Cochrane
Library

Cochrane Database of Systematic Reviews

Pneumococcal conjugate vaccines for preventing otitis media (Review)

Jansen AGSC, Hak E, Veenhoven RH, Damoiseaux RAMJ, Schilder AGM, Sanders EAM

Jansen AGSC, Hak E, Veenhoven RH, Damoiseaux RAMJ, Schilder AGM, Sanders EAM.

Pneumococcal conjugate vaccines for preventing otitis media.

Cochrane Database of Systematic Reviews 2009, Issue 2. Art. No.: CD001480.

DOI: 10.1002/14651858.CD001480.pub3.

www.cochranelibrary.com

TABLE OF CONTENTS

HEADER	1
ABSTRACT	1
PLAIN LANGUAGE SUMMARY	2
BACKGROUND	2
OBJECTIVES	3
METHODS	3
RESULTS	4
DISCUSSION	6
AUTHORS' CONCLUSIONS	8
ACKNOWLEDGEMENTS	8
REFERENCES	9
CHARACTERISTICS OF STUDIES	11
ADDITIONAL TABLES	16
WHAT'S NEW	20
HISTORY	20
CONTRIBUTIONS OF AUTHORS	20
DECLARATIONS OF INTEREST	21
SOURCES OF SUPPORT	21
NOTES	21
INDEX TERMS	21

Pneumococcal conjugate vaccines for preventing otitis media

Angelique GSC Jansen¹, Eelko Hak², Reinier H Veenhoven³, Roger AMJ Damoiseaux⁴, Anne GM Schilder⁵, Elisabeth AM Sanders¹

¹Department of Pediatric Immunology and Infectious Diseases, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, Netherlands. ²Department of Epidemiology, University Medical Center Groningen, Groningen, Netherlands. ³Department of Pediatrics, Spaarne Hospital Haarlem, Haarlem, Netherlands. ⁴De Hof van Blom, Hattem, Netherlands. ⁵Department of Otorhinolaryngology & Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, Netherlands

Contact address: Angelique GSC Jansen, Department of Pediatric Immunology and Infectious Diseases, Wilhelmina Children's Hospital, University Medical Center Utrecht, PO Box 85090, Utrecht, 3508 AB, Netherlands. a.g.s.c.jansen@umcutrecht.nl.

Editorial group: Cochrane Acute Respiratory Infections Group.

Publication status and date: Edited (no change to conclusions), published in Issue 10, 2010.

Citation: Jansen AGSC, Hak E, Veenhoven RH, Damoiseaux RAMJ, Schilder AGM, Sanders EAM. Pneumococcal conjugate vaccines for preventing otitis media. *Cochrane Database of Systematic Reviews* 2009, Issue 2. Art. No.: CD001480. DOI: 10.1002/14651858.CD001480.pub3.

Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

Background

Acute otitis media (AOM) is a very common early infancy and childhood disease. The marginal benefits of antibiotics on AOM, the increasing problem of bacterial resistance to antibiotics, and the huge estimated direct and indirect annual costs associated with otitis media (OM) have prompted a search for effective vaccines to prevent AOM.

Objectives

To assess the effect of pneumococcal conjugate vaccines (PCVs) in preventing AOM in children up to 12 years of age.

Search methods

We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (*The Cochrane Library* 2007, issue 2), which contains the Cochrane Acute Respiratory Infections Group's Specialised Register; MEDLINE (January 1995 to November 2007); and EMBASE (January 1995 to November 2007).

Selection criteria

Randomised controlled trials of PCVs to prevent AOM in children aged 12 years or younger, with a follow up of at least six months after vaccination.

Data collection and analysis

Three review authors independently assessed trial quality and two review authors extracted data.

Main results

We included seven trials on 7- to 11-valent PCV (with different carrier proteins). There was large heterogeneity regarding study population, type of conjugate vaccine, and outcome measures between trials, therefore, results were not pooled. The only currently licensed 7-valent PCV Prevenar® with CRM197 as carrier protein (CRM197-PCV7) administered during infancy was in two studies associated with a 6% (95% confidence interval (CI) -4% to 16%) and 7% (95% CI 4% to 9%) relative reduction in risk of AOM episodes. Another 7-valent PCV with the outer membrane protein complex of *Neisseria meningitidis* (*N. meningitidis*) serogroup B as carrier protein, administered in infancy, did not reduce overall AOM episodes, while an 11-valent PCV with *Haemophilus influenzae*

(*H. influenzae*) protein D as carrier protein was associated with a relative reduction in risk of AOM episodes of 34% (95% CI 21% to 44%). 9-valent PCV (with CRM197 carrier protein) administered in healthy toddlers was associated with a 17% (95% CI -2% to 33%) relative reduction in risk of OM episodes. CRM197-PCV7 followed by 23-valent pneumococcal polysaccharide vaccination administered after infancy in older children with a history of AOM showed no beneficial effect on further AOM episodes.

Authors' conclusions

Based on current evidence of the effectiveness of PCVs for the prevention of AOM, the currently licensed 7-valent PCV administered during infancy has marginal beneficial effects. Discrete reductions of 6% to 7% may mean substantial reductions from a public health perspective. Administering PCV7 in older children with a history of AOM appears to have no benefit in preventing further episodes.

PLAIN LANGUAGE SUMMARY

Pneumococcal conjugate vaccines for preventing otitis media

Acute otitis media (AOM) is the infection of the middle ear and is one of the most common diseases in childhood. Infection with pneumococci (a type of bacterium) is a frequent cause of AOM. Pneumococcal conjugate vaccines (PCVs) aim to immunise young children against pneumococcal infections. This review of seven trials with 46,885 participating children aimed to assess the effects of PCV in preventing AOM. The only currently licensed 7-valent PCV given in infancy reduced the occurrence of AOM episodes by 6% to 7%. This means only a marginal decrease in AOM episodes for the individual, but this may have a substantial impact on the healthcare burden of AOM. Children with a history of AOM do not seem to benefit from 7-valent PCV when immunised at an older age (outside infancy).

BACKGROUND

Description of the condition

Acute otitis media (AOM), defined as effusion in the middle ear accompanied by one or more signs of acute inflammation in the middle ear, such as otalgia, otorrhoea, fever, or irritability, is one of the most common diseases in childhood, posing a large burden on public health. It has a peak incidence in six- to 11-month-olds (Teele 1989). By the age of one year, 62% of infants have experienced at least one episode of AOM, and by the age of two years up to 5% of all children have experienced recurrent episodes of AOM, defined as at least four AOM episodes within one year (Kvaerner 1997; Teele 1989). The three main bacterial pathogens isolated from the middle ear fluid of children with AOM are *Streptococcus pneumoniae* (*S. pneumoniae*) (25% to 39%), (non-typeable) *Haemophilus influenzae* (*H. influenzae*) (12% to 23%), and *Moraxella catarrhalis* (*M. catarrhalis*) (4% to 15%) (Bluestone 1992; Heikkinen 1999; Jacobs 1998; Luotonen 1981).

Description of the intervention

The marginal benefits of antibiotics on AOM (Rovers 2006; Spiro 2008), the increasing problem of bacterial resistance against antibiotics (Arason 1996; Dagan 2000; Del Castillo 1998; Goossens 2007), and the high estimated direct and indirect annual costs associated with otitis media (OM) (Kaplan 1997; Niemela 1999) have prompted a search for effective vaccines to prevent AOM.

How the intervention might work

With pneumococcus being the most common bacterial cause of AOM and childhood pneumonia, and one of the most common causes of invasive bacterial disease such as meningitis, research has focused on the prevention of pneumococcal infections with pneumococcal vaccines. Pneumococcal polysaccharide vaccines (PPVs) have been available for decades, but have shown to be poorly immunogenic in children below the age of two years which are most prone to pneumococcal infections. The first pneumococcal conjugate vaccines (PCVs) in which the pneumococcal capsular serotypes are covalently conjugated to carrier proteins were developed in the 1990s and proved to be adequately immunogenic in infants and toddlers (Dagan 1997; Eskola 1999; Shinefield 1999). The focus in research shifted from the use of PPVs to PCVs in children, and the role of PPVs in the prevention of AOM in chil-

dren has merely been assessed following PCVs and not as a primary intervention anymore. Therefore, the focus of the current review has shifted from the effect of PPVs to the effect of PCVs on AOM. No further attention will be paid to the effect of PPVs, which was described in prior versions of this review (Straetemans 2003).

OBJECTIVES

The aim of this review was to assess the effect of PCVs in preventing AOM in children up to 12 years of age.

METHODS

Criteria for considering studies for this review

Types of studies

Randomised controlled clinical trials of PCVs with prevention of AOM as an outcome in children aged 12 years or younger, and a follow up after vaccinations of at least six months.

Types of participants

Children up to 12 years of age.

Types of interventions

Multivalent PCVs.

Types of outcome measures

The primary outcomes considered are the frequency of all AOM episodes, pneumococcal AOM, and serotype-specific AOM, and the proportion of children with frequent AOM (defined as at least three episodes in the last six months or at least four episodes in the last year).

Search methods for identification of studies

Electronic searches

We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (*The Cochrane Library* 2007, issue 2), which contains the Cochrane Acute Respiratory Infections Group's Specialised Register; MEDLINE (January 1995 to November 2007); and EMBASE (January 1995 to November 2007).

We used the following search strategy for searching MEDLINE and CENTRAL, and modified terms for searching EMBASE.

MEDLINE

```
#1 explode 'bacterial-vaccine' / all subheadings
#2 explode 'bacterial AND vaccine' / all subheadings
#3 explode 'Pneumococcus-vaccine' / all subheadings
#4 pneumococc* near immunity*
#5 pneumococc* near vaccin*
#6 #1 or #2 or #3 or #4 or #5
#7 explode 'otitis media' / all subheadings
#8 (otitis media in ti) or (otitis media in ab)
#9 #7 or #8
#10 #6 or #9
#11 explode 'randomised-controlled-trial' / all subheadings
#12 explode 'controlled-study' / all subheadings
#13 explode 'randomisation' / all subheadings
#14 explode 'single-blind-procedure' / all subheadings
#15 explode 'double-blind-procedure' / all subheadings
#16 explode 'crossover-procedure' / all subheadings
#17 explode 'phase-3-clinical-trial' / all subheadings
#18 (control* near trial*) in ti
#19 (control* near trial*) in ab
#20 (singl* or doubl* or trebl* or tripl*) near ((blind* or mask*) in ti)
#21 (singl* or doubl* or trebl* or tripl*) near ((blind* or mask*) in ab)
#22 random* near ((allocat* or assign*) in ti)
#23 random* near ((alsocat* or assign*) in ab)
#24 #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23
#25 #10 and #24
```

Searching other resources

We also identified studies by checking the bibliographies of all studies and review articles retrieved. We imposed no language restrictions on the searches.

Data collection and analysis

Study quality and data extraction

Three review authors (AJ, LS and EH) assessed quality of the included studies using a three-item quality scale with a score range from zero to five (Jadad 1996). According to the Jadad criteria, one point was allocated for randomisation, double blinding and description of withdrawals and dropouts; an extra point was added for methods of randomisation and blinding that are well described and adequate. Studies that used a clearly inadequate method of

randomisation or blinding lost the point allocated. We resolved disagreement by discussion. The Jadad score may vary from zero to five, equalising the minimal and maximal quality score accomplished. The same authors performed data extraction independently, and resolved differences by consensus.

Data analysis

Meta-analysis by pooling the results of the different studies is only useful and justified when studies show satisfactory clinical homogeneity in terms of study population, setting, intervention and outcome measures. We assessed clinical heterogeneity between studies by reviewing the differences across trials. There was considerable clinical heterogeneity in the trials in terms of the study populations, outcome measures, and the type of PCV regarding carrier protein and valency (see 'Description of studies' below). Therefore, we decided a meta-analysis was not appropriate.

We briefly describe the methods we would have used if we pooled the results. The generalised Cox proportional hazard method proposed by Anderson and Gill (Andersen 1982) is regarded as the most appropriate to assess the effect of PCVs on AOM (Jahn-Eimermacher 2007). Under the assumptions that the hazard rate is proportional between both groups over time, and that the risk of AOM is not affected by previous episodes (although this assumption is most likely not true), this model takes all available information into account; that is, all episodes (also the recurrent ones), differences in individual patient follow-up time, and time until a case of AOM (Jahn-Eimermacher 2007). However, information on individual follow-up time until the first, second, third, etc case of AOM is hard to obtain for each study to be included in the meta-analysis. Poisson regression is based on the assumptions of a constant risk of AOM over time and that this risk is not affected by previous episodes of AOM. This method only requires the total follow-up time and total number of episodes and appears therefore a more feasible method to meta-analyse. Furthermore, Poisson regression seems not to be affected by the deviation from a constant risk over time, having very similar results for the effect of PCVs on AOM to the Anderson-Gill approach (Jahn-Eimermacher 2007). For Poisson regression, the treatment effect is measured as a rate ratio defined as follows: (total AOM episodes in pneumococcal vaccination group divided by the number of children in the pneumococcal vaccination group multiplied by the follow-up time in months) divided by (total AOM episodes in control group divided by the number of children in the control group multiplied by the follow-up time in months) (McCullagh 1989).

RESULTS

Description of studies

The MEDLINE search yielded eight potentially relevant randomised trials after screening of the title and abstract (Black 2000; Dagan 2001; Eskola 2001; Fireman 2003; Kilpi 2003; Prymula 2006; Van Kempen 2006; Veenhoven 2003). We found no additional potentially relevant trials in either CENTRAL or the Cochrane Acute Respiratory Infections Group Specialised Register. The EMBASE search also did not yield any additional potentially relevant studies.

The eight included papers in this review concerned seven studies in total. Two of these studies (Black 2000/Fireman 2003 and Dagan 2001) had all types of OM (including but not exclusively AOM) as an outcome. Since the effect of PCVs on AOM may be influenced by the age at which the PCV was administered, we will describe the studies accordingly, that is, those with vaccination in infancy and those with vaccination later in childhood. In all studies the control group received a control vaccine. See also the 'Characteristics of included studies' table.

PCV administered in infancy

Three trials including healthy infants studied the effect of PCV administered in infancy on OM. In the Northern California Kaiser Permanente (NCKP) trial (Black 2000/Fireman 2003) and the Finnish Otitis Media (FinOM) trial (Eskola 2001) the treatment group was administered the 7-valent PCV, containing the polysaccharides of seven serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F coupled to the carrier protein CRM197 (a non-toxic mutant of diphtheria toxin) (CRM197-PCV7), at the age of two, four and six months, and 12 to 15 months. In the NCKP trial, infants were enrolled over a period of almost three years and had a follow-up time varying from about eight months to 3.5 years. The trial was originally designed to investigate the effect of CRM197-PCV7 on invasive pneumococcal disease, and OM was a secondary outcome. Clinical diagnoses of OM were obtained from a computerised database collecting department-specific diagnosis checklists routinely marked by emergency physicians and paediatricians in the NCKP population. All clinical diagnoses of 'otitis media', 'otitis media, acute', 'middle ear effusion', 'otitis media, serous', or 'otitis media with effusion' were included. The FinOM trial primarily aimed to assess the effect on AOM. Infants were followed until the age of 24 months, and parents were encouraged to bring their child to the study clinic (established specifically for the purpose) for evaluation of symptoms suggesting respiratory infection or AOM. The diagnosis of AOM was standardised.

Kilpi 2003 describes another part of the FinOM trial in which the index group was administered another 7-valent PCV, containing capsular polysaccharides of the same seven serotypes as CRM197-PCV7 conjugated to the outer membrane protein complex of *Neisseria meningitidis* (*N. meningitidis*) serogroup B (OMPC-PCV7). Additionally, 22% of the children assigned to OMPC-PCV7 received PPV23 at the age of 12 months instead of a fourth OMPC-

PCV7 dose. The follow up and outcome measure was similar to Eskola 2001. Finally, in Prymula 2006 (POET trial) an 11-valent PCV was administered at the ages of two, four, five months, and 12 to 15 months, containing the capsular polysaccharides of serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F, conjugated to protein D, which is a surface lipoprotein of *H. influenzae*. Protein D is highly conserved in both encapsulated and non-encapsulated *H. influenzae* strains and therefore has the potential to provide protection against any *H. influenzae* strain that causes OM (Forsgren 2008; Prymula 2006). Follow up continued until the age of 24 to 27 months. The primary aim of the trial was to assess the effect on AOM, and parents were advised to consult their paediatrician if their child was sick, had ear pain, or had spontaneous ear discharge. The diagnosis of AOM was standardised.

PCV administered at a later age

Three trials assessed the effects of PCV administered at a later age on AOM. Dagan 2001 assessed the effect of a 9-valent PCV (containing the capsular polysaccharides of serotypes 1 and 5 besides those included in CRM197-PCV7, conjugated to CRM197) on AOM in healthy daycare attendees aged 12 to 35 months. The vaccine was administered twice in 12- to 17-month-olds and once in 18- to 35-month-olds. The study was undertaken to examine the effect on respiratory infections. In 18 encounters during the two-year follow-up period that started one month after complete immunisation, parents were questioned about illness episodes, including OM episodes. The OM diagnosis was not physician confirmed and not standardised. Van Kempen 2006 and Veenhoven 2003 assessed the effect of pneumococcal vaccination on AOM in children aged one to seven years with a history of at least two AOM episodes in the year prior to study entry. CRM197-PCV7 was administered twice in one- to two-year-olds and once in two- to seven-year-olds followed by PPV23 (containing capsular polysaccharides of the serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F) six to seven months later. Children with underlying illnesses including immunocompromising conditions were excluded. Both studies had a similar design, were conducted in parallel but were analysed separately due to differences in study population (children included in Van Kempen 2006 had a more severe history of AOM and more often tympanostomy tube placement prior to study entry). Follow-up lasted about 24 months. Parents were instructed to visit the study clinics or their family physician, otolaryngologists, or paediatrician for assessment in case of symptoms suggesting AOM. Physicians registered signs and symptoms of every AOM episode on standard registration forms. The diagnosis of AOM was standardised.

Risk of bias in included studies

Table 1 shows the results of the quality assessment by the Jadad

method (Jadad 1996). Dagan 2001, Van Kempen 2006 and Veenhoven 2003 had a maximum quality score of five. Kilpi 2003 scored four points because this article failed to report withdrawals and dropouts, while adequately reporting the randomisation and double-blinding methods. Prymula 2006 scored four points and missed one point due to no reporting of double-blinding methods. Black 2000 and Fireman 2003 had a quality score of two. Both articles failed to report withdrawals and dropouts, and no additional points could be given for adequate reporting of the method to generate the sequence of randomisation and the method of double blinding. Eskola 2001 had a score of two for similar reasons. Although this study reported the number of withdrawals and dropouts, no reasons were given for them.

This review will present the results of the trials as reported in the published papers since meta-analysis was decided to be inappropriate due to heterogeneity in study population, intervention and outcome measure. Therefore the statistical methods by which the data were analysed in each study are shortly assessed. Black 2000, Eskola 2001, Fireman 2003, Kilpi 2003, Prymula 2006, Van Kempen 2006 and Veenhoven 2003 all used the generalised Cox proportional hazard method proposed by Anderson and Gill 1982 (Andersen 1982), currently regarded most optimal to analyse this kind of data (see 'Data collection and analysis' section above). Dagan 2001 compared rates of AOM, but rather than comparing them by Poisson regression (which would presumably yield results similar to those obtained with the Anderson and Gill approach), the chi-square test was used, which is suboptimal for comparing rates.

Effects of interventions

In total, we included seven trials with 46,885 participating children, ranging from 74 to 37,868 participants per study. Four studies included infants who received primary vaccinations before six months of age (46,164 participants in total) (Black 2000/Fireman 2003; Eskola 2001; Kilpi 2003; Prymula 2006); one study included daycare attendees aged 12 to 35 months (264 participants) (Dagan 2001), and two included one- to seven-year-olds with a history of AOM (457 participants in total) (Van Kempen 2006; Veenhoven 2003).

In four studies the licensed CRM197-PCV7 was used as intervention (Black 2000/Fireman 2003; Eskola 2001; Veenhoven 2003; Van Kempen 2006), and in two of these studies boosting with 23-valent PPV was given (Van Kempen 2006; Veenhoven 2003). The other three studies each had different interventions, i.e. a 9-valent PCV with CRM197 as protein carrier (Dagan 2001), a 7-valent PCV with the outer membrane complex of *N. meningitidis* serogroup B as protein carrier (Kilpi 2003), and an 11-valent PCV with protein D as protein carrier (Prymula 2006).

All studies had a control group that was given a control vaccine (meningococcus type C conjugate vaccine, hepatitis A vaccine or hepatitis B vaccine). Five studies applied a standardised diagnosis of AOM (Eskola 2001; Kilpi 2003; Prymula 2006; Van Kempen 2006; Veenhoven 2003), whereas in one study, AOM episodes were extracted from a computerised data source containing all visits registered by physicians (Black 2000/Fireman 2003) and another study assessed parent-reported AOM episodes (Dagan 2001). Five studies additionally assessed the effect of PCVs on pneumococcal AOM (Black 2000/Fireman 2003; Eskola 2001; Kilpi 2003; Prymula 2006; Veenhoven 2003). Three studies cultured middle ear fluid from all AOM episodes (Eskola 2001; Kilpi 2003; Prymula 2006), whereas one study only cultured it from the first AOM episode (Veenhoven 2003), and another study assessed the effect on reported cultures that were taken in cases of spontaneously draining ears (Black 2000/Fireman 2003). Three studies reported on the effects of PCVs on recurrent AOM (Black 2000/Fireman 2003; Eskola 2001; Prymula 2006).

It should be noted that we have presented the results of the trials included in this review as reported in the published papers and that the presentation of results varied between trials. Where possible we have reported the incidences of the various outcomes in the study arms together with the efficacy estimates with 95% CIs. However, due to limitations of the data, we have reported alternative statistical measures in some instances. Most studies reported efficacy estimates on the basis of per-protocol-analysis with or without noting that estimates on the basis of intention-to-treat-analysis were similar.

See also Table 2, Table 3, and Table 4 for the efficacy estimates of PCVs on all AOM episodes, pneumococcal AOM, and recurrent AOM respectively.

Effect of PCV administered in infancy

The NCKP and FinOM trials in which CRM197-PCV7 was administered during infancy showed that CRM197-PCV7 reduced overall AOM episodes by 6% to 7% (Eskola 2001; Fireman 2003), whereas OMPC-PCV7 appeared to have no effect on overall AOM episodes (Kilpi 2003). The administration of protein D PCV11 during infancy was associated with a 34% reduction in AOM episodes (Prymula 2006).

Efficacy of PCVs administered in infancy against pneumococcal AOM varied from 25% for OMPC-PCV7 (Kilpi 2003), 34% for CRM197-PCV7 (Eskola 2001), to 52% for protein D PCV11 (Prymula 2006). The reduction of vaccine-type pneumococcal AOM was fairly similar with 56% to 67% (Black 2000; Eskola 2001; Kilpi 2003; Prymula 2006). Administration of CRM197-PCV7 and protein D PCV11 also seemed to reduce AOM caused by the so-called cross-reactive serotypes which are non-vaccine serotypes with a serogroup that is included in the vaccine (Eskola 2001; Prymula 2006), while OMPC-PCV7 failed to show cross-protection (Kilpi 2003). Although not statistically significant,

the administration of CRM197-PCV7 and OMPC-PCV7 was associated with an increase in non-vaccine-type AOM (replacement) (Eskola 2001; Kilpi 2003) and *H. influenzae* AOM while the protein D PCV11 did not show pneumococcal replacement and showed vaccine efficacy of 35% against *H. influenzae* AOM (Prymula 2006).

CRM197-PCV7 seemed to reduce recurrent AOM by 9% (Black 2000; Eskola 2001), whereas the administration of protein D PCV11 was associated with a statistically non-significant decrease of 56% in recurrent AOM (Prymula 2006).

Effect of PCV administered at a later age

9-valent PCV administered in healthy 12- to 35-month-olds appeared to reduce overall OM episodes by 17% (Dagan 2001), while CRM197-PCV7 followed by PPV23 in one- to seven-year-olds with a history of AOM did not reduce the occurrence of further AOM episodes (Van Kempen 2006; Veenhoven 2003). With respect to pneumococcal AOM, only one study reported the effect of CRM197-PCV7 followed by PPV23 on pneumococcal AOM (Veenhoven 2003): pneumococcal AOM was reduced by 33%, vaccine-type AOM by 56%, and non-vaccine type AOM by 17%, although none of the estimates was statistically significant (small numbers). None of the three trials in older children reported the effect of the PCV on recurrent AOM.

DISCUSSION

The trials on the effect of PCV on AOM in children show large heterogeneity regarding study population (age of administration of PCV), intervention (vaccine valency (7-/9-/11-valent vaccines), carrier protein (CRM197, OMPC or protein D), presence or absence of additional booster immunisation with PCV or PPV23, and outcomes (active surveillance for standardised physician-diagnosed AOM, passive collection of diagnoses of AOM or parent-reported AOM). Furthermore, in the infant studies on AOM focusing on bacteriology (Eskola 2001; Kilpi 2003; Prymula 2006) the control groups varied markedly in the proportions of *S. pneumoniae*, *H. influenzae* and *M. catarrhalis* in middle ear fluid, possibly related to time and geographic region as well as case definition which will affect the result of overall AOM episodes prevented by pneumococcal vaccines. Additionally, two studies (Van Kempen 2006; Veenhoven 2003) included older otitis-prone children with tympanostomy tubes, so the intervention was aimed at secondary or even tertiary, not primary prevention.

The currently licensed CRM197-PCV7, a 7-valent pneumococcal conjugate vaccine with CRM197 as carrier protein, administered in infancy was associated with a 6% to 7% reduction in AOM episodes (Eskola 2001; Fireman 2003). The 7-valent PCV with OMPC as carrier protein appeared to have less effect on

AOM episodes overall than CRM197-PCV7 (Kilpi 2003). This despite the fact that both 7-valent vaccines appeared to have a similar effect on vaccine-serotype pneumococcal AOM of 56% and 57% (Eskola 2001; Kilpi 2003). However, CRM197-PCV7 also showed cross-protection to vaccine-related serotypes, in particular to the very common vaccine-related 6A serotype (Eskola 2001), while OMPC-PCV7 showed no efficacy at all against vaccine-related serotypes like 6A (Kilpi 2003). For both 7-valent vaccines, there was a tendency of replacement disease by non-vaccine pneumococci as well as by other otopathogens like *H. influenzae*. Furthermore, in the OMPC-PCV7 arm of the FinOM trial, the proportion of AOM caused by *M. catarrhalis* also increased (Kilpi 2003). This means that PCVs are effective against vaccine-serotype pneumococci, but in AOM there is high potential for replacement by other pathogens that are common colonisers of the nasopharynx. CRM197-PCV7 is known to affect nasopharyngeal carriage of pneumococci, with a shift from vaccine-type pneumococci to non-vaccine-type pneumococci and other bacterial pathogens that may have pathogenic potential (Block 2006; Eskola 2001; Obaro 1996; Veenhoven 2003; Veenhoven 2004). The middle ear is directly connected to the nasopharynx and by lowering the carriage of vaccine-type pneumococci, a niche is created for other bacteria with a pathogenic potential (Block 2006; Veenhoven 2003; Veenhoven 2004).

Although the vaccine-related serotypes, mostly notably 6A and 19A, were reduced after CRM197-PCV7 in the FinOM trial (Eskola 2001), the name 'cross-protection' by the vaccine should probably be abandoned. In post-marketing studies after licensure of CRM7-PCV7 in the US in 2000, an increase in serotype 19A in invasive pneumococcal disease as well as an increase in serotype 6A and 19A involved in AOM was observed (Block 2004; Hicks 2007; McEllistrem 2005; Pichichero 2007). Both upcoming ear pathogens (pneumococcal serotypes 6A and 19A) are included in a 13-valent CRM197-conjugate vaccine that is under development.

The POET trial with an 11-valent PCV with protein D as carrier protein administered to infants, reported the largest reduction in overall AOM episodes of 34% (Prymula 2006). Compared to the 6% to 7% reduction in studies with CRM197-PCV, this effect is rather large and may not be solely explained by the four additional serotypes covered by the 11-valent PCV compared to CRM197-PCV7. Part of the effect may be related to the protein D to which the polysaccharides are conjugated in the vaccine. Protein D has the potential to provide protection against any *H. influenzae* strain that causes OM (Forsgren 2008; Prymula 2006). Indeed, the 11-valent PCV with protein D as carrier protein was demonstrated to reduce non-typeable *H. influenzae* by 35% (95% CI 2 to 57) (Prymula 2006). Furthermore, an effect against vaccine-related serotypes was observed in the POET trial and remarkably, no replacement by non-vaccine serotypes was demonstrated. It should be noted that in the POET trial children diagnosed with AOM by the paediatrician were subsequently referred to the otorhinolaryn-

gologist for confirmation and collection of middle ear fluid, while in the FinOM trial middle ear fluid was collected from every child with a diagnosis of AOM during the same visit. This may have contributed to the large difference in AOM incidence between these studies with incidence rates reported by Prymula 2006 being about ten times lower than the incidence reported by Eskola 2001. It might be that in the POET trial the more severe episodes of AOM were identified and consequently the effect may only apply to these more severe episodes. The case definition potentially also introduced a different selection of pathogens.

Only one trial reported on the effects of PCV on AOM in older healthy children, daycare attendees (Dagan 2001). After administration of a 9-valent PCV with CRM197 as carrier protein, a 17% reduction in AOM was observed. However, in this study the outcome measure (parent-reported AOM) and the statistics were suboptimal. The other studies in older children aged one to seven years concern children with a history of AOM (Van Kempen 2006; Veenhoven 2003). In these studies, the administration of CRM197-PCV7 was followed by PPV23, and both showed no beneficial effect on further AOM episodes overall after the PPV booster. In contrast, in the infant studies with CRM197-PCV7 but without the PPV23 booster, a protective effect on the number of children developing recurrent episodes of AOM up to 16% was demonstrated. This was also reflected in a 20% reduction of tympanostomy tube placement (Black 2000; Fireman 2003). The point estimate of vaccine efficacy in the children vaccinated at an older age but after previous AOM episodes indicated a similar reduction of AOM caused by vaccine-serotypes to the FinOM study with CRM197-PCV7 (Eskola 2001; Kilpi 2003; Veenhoven 2003). Furthermore, a significant and adequate nasopharyngeal carriage reduction of vaccine-type pneumococci was observed (Veenhoven 2004). The reduced efficacy of CRM197-PCV7 in children already with a history of AOM may be explained by an increased susceptibility to subsequent infections, not only with non-vaccine type pneumococci but also other nasopharyngeal colonisers, due to 'damages' already suffered by the middle ear mucosa caused by prior AOM (Veenhoven 2003). Thus, it appears that the age at which PCV is administered and/or a history of AOM episodes modifies the effect of PCV on AOM, despite the fact that age alone could not be identified as a statistically significant effect modifier (Fireman 2003; Veenhoven 2003).

The real-world experience gained with widespread CRM197-PCV7 vaccination in infants after 2000 in the United States suggests that the impact on AOM may be much greater than that seen in the clinical studies. Post-licensure studies comparing rates of ambulatory visits and antibiotic prescriptions related to AOM in the immediate years before and following widespread implementation of routine CRM197-PCV7 vaccination in children younger than two years of age, found a reduction of 42.7% and 41.9% respectively (Zhou 2008), and another study found a decline in frequent OM of 17% and 28% in birth cohorts from Tennessee

and upstate New York (Poehling 2007). These much higher benefits might be due to indirect herd effects and may have important implications for the cost-effectiveness analyses for conjugate vaccines. However, in a recent study in the Boston area, the decline of uncomplicated AOM, as well as (OM) treatment failure and AOM relapse showed that the decline was at least as much in the period 1996 to 2000 as from 2000 to 2004 and therefore the role of PCV implementation for OM may be modest (Sox 2008).

Whether the decline in OM will continue or wane with time is relevant and deserves ongoing monitoring. A waning effect in OM incidence after implementation of conjugate vaccinations may be explained by replacement by other otopathogens like *H. influenzae* or an increase in the proportion of OM caused by non-vaccine serotypes including serotypes 3, 6A and 19A (Block 2004; McEllistrem 2005; Pichichero 2007). As previously mentioned, two infant studies found an increase in non-vaccine-type pneumococcal AOM after administration of 7-valent PCV, albeit not statistically significant, as well as an increase of *H. influenzae* (Eskola 2001; Kilpi 2003). An increase in *H. influenzae* was also observed in the postmarketing studies on AOM in the United States (Block 2004; Casey 2004). In addition, the study in older children with previous AOM episodes demonstrated an increase of AOM caused by *Staphylococcus aureus* (*S. aureus*) (Veenhoven 2003). Continuing research after the effects of PCV on nasopharyngeal carriage and on AOM before and after the introduction of CRM197-PCV7 in national infant immunisation protocols is therefore of utmost importance.

AUTHORS' CONCLUSIONS

Implications for practice

When administered in infancy, PCVs appear to have some protective effect against AOM, depending on the type of PCV used. At present, CRM197-PCV7, a 7-valent PCV with CRM197 as carrier protein, is the only PCV licensed for use in young children. The prevention of invasive pneumococcal disease has been the primary reason for many Western countries to introduce CRM197-PCV7 into their national infant immunisation protocol. The beneficial effect on overall AOM episodes with the currently licensed 7-valent vaccine appears marginal with a 6% to 7% reduction, and therefore promoting CRM197-PCV7 solely to reduce AOM for the individual does not seem justified. However, from a public health perspective, because AOM is so common, even such small reductions may substantially reduce the health care burden caused by AOM.

For countries that have not yet implemented CRM197-PCV7 into the immunisation protocol and for countries that did not implement a catch-up vaccination programme for older children up to five years of age, the question is whether it would be beneficial

to administer the vaccine to older children with a history of AOM. The two trials in older children with a history of AOM suggested no beneficial effect of CRM197-PCV7 on all further episodes of AOM (Van Kempen 2006; Veenhoven 2003), and consequently, there is no reason at present to administer older children with a history of previous AOM episodes the vaccine in order to protect them against further AOM episodes. In fact, early vaccination before the first AOM episode may be required for prevention of middle ear mucosal damage.

Implications for research

The Jadad quality analysis is very sensitive to written information from published manuscripts. Most studies included in this review lost points because the method of randomisation or blinding was not described. Also, often points were lost because the reasons for withdrawals and dropouts were not described. Future publications of trials should clearly report these items.

In view of the ongoing development of new PCVs and studies on these, we emphasise the need for uniform outcome measures (case definitions of AOM) and presentation of results to allow for meta-analysis by pooling the results in future. Reporting of the total number of AOM episodes in the different study arms, together with the total follow-up time in person-months is required. These figures should also be available on the basis of intention-to-treat analysis and not only on the basis of per-protocol-analysis.

Eleven-valent PCV with protein D as carrier protein appears promising in the prevention of AOM, and currently trials are initiated to determine the effect of this vaccine on pneumococcal disease. Also the newly developed 13-valent PCV (with CRM197 as carrier protein and the additional serotypes 1, 3, 5, 6A, 7F, and 19A besides those included in CRM197-PCV7) may mean an improvement in the protection against pneumococcal infections, including AOM.

In view of the effects of PCVs on nasopharyngeal carriage of pathogens, awareness of the possibility of infections caused by replacing pathogens is warranted. Besides reduction of nasopharyngeal vaccine-type serotypes which is presumed to induce herd effects, replacing pneumococcal serotypes may not only lead to replacement disease in vaccinees but also in the population. Continuing surveillance of pneumococcal disease in different settings and geographic locations is therefore of utmost importance.

ACKNOWLEDGEMENTS

We would like to thank Masja Straetemans and Gerhard Zielhuis for their contributions to prior versions of this review. We would also like to thank the following people for commenting on the update of this review: Barbara Loe Fisher, Morio Aihara, Mark Jones, and Paul Glasziou.

REFERENCES

References to studies included in this review

Black 2000 *{published data only}*

Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. *Pediatric Infectious Disease Journal* 2000;**19**(3):187–95.

Dagan 2001 *{published data only}*

Dagan R, Sikuler-Cohen M, Zamir O, Janco J, Givon-Lavi N, Fraser D. Effect of a conjugate pneumococcal vaccine on the occurrence of respiratory infections and antibiotic use in day-care center attendees. *Pediatric Infectious Disease Journal* 2001;**20**(10):951–8.

Eskola 2001 *{published data only}*

Eskola J, Kilpi T, Palmu A, Jokinen J, Haapakoski J, Herva E, et al. Efficacy of a Pneumococcal Conjugate Vaccine against Acute Otitis Media. *New England Journal of Medicine* 2001;**344**(6):403–9.

Fireman 2003 *{published data only}*

Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group [see comments]. *Pediatric Infectious Disease Journal* 2000;**19**(3):187–95.

* Fireman B, Black SB, Shinefield HR, Lee J, Lewis E, Ray P. Impact of the pneumococcal conjugate vaccine on otitis media. *Pediatric Infectious Disease Journal* 2003;**22**:10–6.

Kilpi 2003 *{published data only}*

Kilpi T, Ahman H, Jokinen J, Lankinen KS, Palmu A, Savolainen H, et al. Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine in 1666 children. *Clinical Infectious Diseases* 2003;**37**(9):1155–64.

Prymula 2006 *{published data only}*

Prymula R, Peeters P, Chrobok V, Kriz P, Novakova E, Kaliskova E, et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both *Streptococcus pneumoniae* and non-typeable *Haemophilus influenzae*: a randomised double-blind efficacy study. *Lancet* 2006;**367**(9512):740–8.

Van Kempen 2006 *{published data only}*

Van Kempen MJ, Vermeiren JS, Vaneechoutte M, Claeys G, Veenhoven RH, Rijkers GT, et al. Pneumococcal conjugate vaccination in children with recurrent acute otitis media: a therapeutic alternative?. *International Journal of Pediatric Otorhinolaryngology* 2006;**70**(2):275–85.

Veenhoven 2003 *{published data only}*

Veenhoven R, Bogaert D, Uiterwaal C, Brouwer C, Kiezebrink H, Bruin J, et al. Effect of conjugate

pneumococcal vaccine followed by polysaccharide pneumococcal vaccine on recurrent acute otitis media: a randomised study. *Lancet* 2003;**361**(9376):2189–95.

Additional references

Andersen 1982

Andersen PK, Gill RD. Cox regression model for counting processes: a large sample study. *The Annals of Statistics* 1982;**10**(4):1100–20.

Arason 1996

Arason VA, Kristinsson KG, Sigurdsson JA, Stefánsdóttir G, Mölstað S, Gudmundsson S. Do antimicrobials increase the carriage rate of penicillin resistant pneumococci in children? Cross sectional prevalence study. *BMJ* 1996;**313**(7054):387–91.

Block 2004

Block SL, Hedrick J, Harrison CJ, Tyler R, Smith A, Findlay R, et al. Community-wide vaccination with the heptavalent pneumococcal conjugate significantly alters the microbiology of acute otitis media. *The Pediatric Infectious Disease Journal* 2004;**23**(9):829–33.

Block 2006

Block SL. Searching for the Holy Grail of acute otitis media. *Archives of Diseases in Childhood* 2006;**91**(12):959–61.

Bluestone 1992

Bluestone CD, Stephenson JS, Martin LM. Ten-year review of otitis media pathogens. *Pediatric Infectious Disease Journal* 1992;**11**(8 Suppl):7–11.

Casey 2004

Casey JR, Pichichero ME. Changes in the frequency and pathogens causing acute otitis media in 1995–2003. *Pediatric Infectious Disease Journal* 2004;**9**:824–8.

Dagan 1997

Dagan R, Melamed R, Zamir O, Leroy O. Safety and immunogenicity of tetravalent pneumococcal vaccines containing 6B, 14, 19F and 23F polysaccharides conjugated to either tetanus toxoid or diphtheria toxoid in young infants and their boosterability by native polysaccharide antigens. *Pediatric Infectious Disease Journal* 1997;**16**(11):1053–9.

Dagan 2000

Dagan R. Treatment of acute otitis media - challenges in the era of antibiotic resistance. *Vaccine* 2000;**19** Suppl 1:9–16.

Del Castillo 1998

del Castillo F, Baquero-Artigao F, Garcia-Perea A. Influence of recent antibiotic therapy on antimicrobial resistance of *Streptococcus pneumoniae* in children with acute otitis media in Spain. *Pediatric Infectious Disease Journal* 1998;**17**(2):94–7.

Eskola 1999

Eskola J, Anttila M. Pneumococcal conjugate vaccines. *Pediatric Infectious Disease Journal* 1999;**18**(6):543–51.

Forsgren 2008

Forsgren A, Riesbeck K, Janson H. Protein D of *Haemophilus influenzae*: a protective nontypeable *H. influenzae* antigen and a carrier for pneumococcal conjugate vaccines. *Clinical Infectious Diseases* 2008;**46**(5):726–31.

Goossens 2007

Goossens H, Ferech M, Coenen S, Stephens P. Comparison of outpatient systemic antibacterial use in 2004 in the United States and 27 European countries. *Clinical Infectious Diseases* 2007;**44**(8):1091–5.

Heikkinen 1999

Heikkinen T, Thint M, Chonmaitree T. Prevalence of various respiratory viruses in the middle ear during acute otitis media. *The New England Journal of Medicine* 1999;**340**(4):260–4.

Hicks 2007

Hicks LA, Harrison LH, Flannery B, Hadler JL, Schaffner W, Craig AS, et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998–2004. *The Journal of Infectious Diseases* 2007;**196**(9):1346–54.

Jacobs 1998

Jacobs MR, Dagan R, Appelbaum PC, Burch DJ. Prevalence of antimicrobial-resistant pathogens in middle ear fluid: multinational study of 917 children with acute otitis media. *Antimicrobial Agents and Chemotherapy* 1998;**42**(3):589–95.

Jadad 1996

Jadad AR, Moore A, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. *Controlled Clinical Trials* 1996;**17**:1–12.

Jahn-Eimermacher 2007

Jahn-Eimermacher A, du Prel JB, Schmitt HJ. Assessing vaccine efficacy for the prevention of acute otitis media by pneumococcal vaccination in children: a methodological overview of statistical practice in randomized controlled clinical trials. *Vaccine* 2007;**25**(33):6237–44.

Kaplan 1997

Kaplan B, Wandstrat TL, Cunningham JR. Overall cost in the treatment of otitis media. *Pediatric Infectious Disease Journal* 1997;**16**(2 Suppl):9–11.

Kvaerner 1997

Kvaerner KJ, Nafstad P, Hagen JA, Mair IW, Jaakkola JJ. Recurrent acute otitis media: the significance of age at onset. *Acta Otolaryngologica* 1997;**117**(4):578–84.

Luotonen 1981

Luotonen J, Herva E, Karma P, Timonen M, Leinonen M, Makela PH. The bacteriology of acute otitis media in children with special reference to *Streptococcus pneumoniae* as studied by bacteriological and antigen detection methods. *Scandinavian Journal Infectious Disease* 1981;**13**(3):177–83.

McCullagh 1989

McCullagh P, Nelder JA. *Generalized linear models*. London: Chapman and Hall, 1989.

McEllistrem 2005

McEllistrem MC, Adams JM, Patel K, Medelsohn AB, Kaplan SL, Bradley JS, et al. Acute otitis media due to penicillin-non-susceptible *Streptococcus pneumoniae* before and after the introduction of the pneumococcal conjugate vaccine. *Clinical Infectious Diseases* 2005;**40**:1738–44.

Niemela 1999

Niemela M, Uhari M, Mottonen M, Pokka T. Costs arising from otitis media. *Acta Paediatrica* 1999;**88**(5):553–6.

Obaro 1996

Obaro SK, Adegbola RA, Banya WA, Greenwood BM. Carriage of pneumococci after pneumococcal vaccination. *Lancet* 1996;**348**(9022):271–2.

Pichichero 2007

Pichichero ME, Casey JR. Emergence of a multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugate vaccine as an otopathogen in children. *JAMA* 2007;**298**:1772–8.

Poehling 2007

Poehling KA, Szilagyi PG, Grijalva CG, Martin SW, LaFleur B, Mitchel E, et al. Reduction of frequent otitis media and pressure-equalizing tube insertions in children after introduction of pneumococcal conjugate vaccine. *Pediatrics* 2007;**119**(4):707–15.

Rovers 2006

Rovers MM, Glasziou P, Appelman CL, Burke P, McCormick DP, Damoiseaux RA, et al. Antibiotics for acute otitis media: a meta-analysis with individual patient data. *Lancet* 2006;**368**(9545):1429–35.

Shinefield 1999

Shinefield HR, Black S, Ray P, Chang I, Lewis N, Fireman B, et al. Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers. *Pediatric Infectious Disease Journal* 1999;**18**(9):757–63.

Sox 2008

Sox CM, Finkelstein JA, Yin R, Kleinman K, Lieu TA. Trends in otitis media treatment failure and relapse. *Pediatrics* 2008;**121**:674–9.

Spiro 2008

Spiro DM, Arnold DH. The concept and practice of a wait-and-see approach to acute otitis media. *Current Opinion in Pediatrics* 2008;**20**(1):72–8.

Teele 1989

Teele DW, Klein JO, Rosner B. Epidemiology of otitis media during the first seven years of life in children in greater Boston: a prospective, cohort study. *Journal Infectious Disease* 1989;**160**:83–94.

Veenhoven 2004

Veenhoven RH, Bogaert D, Schilder AG, Rijkers GT, Uiterwaal CS, Kiezebrink HH, et al. Nasopharyngeal pneumococcal carriage after combined pneumococcal conjugate and polysaccharide vaccination in children with a history of recurrent acute otitis media. *Clinical Infectious Diseases* 2004;**39**(7):911–9.

Zhou 2008

Zhou F, Shefer A, Kong Y, Nuorti JP. Trends in acute otitis media-related health care utilization by privately insured young children in the United States, 1997-2004. *Pediatrics* 2008;**121**:253–60.

References to other published versions of this review**Straetemans 2003**

Straetemans M, Sanders EAM, Veenhoven RH, Schilder AGM, Damoiseaux RAMJ, Zielhuis GA. Review of

randomized controlled trials on pneumococcal vaccination for prevention of otitis media. *Pediatric Infectious Disease Journal* 2003;**22**(6):515–24.

Straetemans 2004

Straetemans M, Sanders EAM, Veenhoven RH, Schilder AGM, Damoiseaux RAMJ, Zielhuis GA. Pneumococcal vaccines for preventing otitis media. *Cochrane Database of Systematic Reviews* 2004, Issue 1. DOI: 10.1002/14651858.CD001480.pub2

* Indicates the major publication for the study

CHARACTERISTICS OF STUDIES

Characteristics of included studies [ordered by study ID]

Black 2000

Methods	Randomised controlled, double-blind trial	
Participants	US multicentre trial of 37,868 healthy infants aged 2 months	
Interventions	7-valent pneumococcal conjugate vaccine (containing the polysaccharides of serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F conjugated to the carrier protein CRM197) at 2, 4, 6, and 12 to 15 months of age versus meningococcus type C conjugate vaccine at similar ages	
Outcomes	Recurrent episodes/visits of otitis media - episodes extracted from a computerised data source containing all visits registered by physicians These were secondary outcomes; the trial was originally designed to assess the effect of the vaccine on invasive pneumococcal disease	
Notes	Fireman 2003 is an extension of this study	
<i>Risk of bias</i>		
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B - Unclear

Dagan 2001

Methods	Randomised controlled, double-blind trial	
Participants	Israeli trial of 264 healthy 12- to 35-month-olds attending eight daycare centres	
Interventions	9-valent pneumococcal conjugate vaccine (containing saccharides of nine serotypes 1, 4, 5, 6B, 9V, 14, 18C, 19F and 23F conjugated to CRM197) twice in 12- to 17-month-olds and once in 18-to 35-month-olds versus meningococcus type C vaccination at similar ages	
Outcomes	Otitis media episodes, parent-reported This was a secondary outcome; primary outcome of the trial was nasopharyngeal carriage of <i>S. pneumoniae</i>	
Notes		
<i>Risk of bias</i>		
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Low risk	A - Adequate

Eskola 2001

Methods	Randomised controlled, double-blind trial
Participants	Finland, multicentre trial of 1662 infants aged 2 months
Interventions	7-valent pneumococcal conjugate vaccine (containing polysaccharides of serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F conjugated to the carrier protein CRM197) at 2, 4, 6, and 12 to 15 months of age versus hepatitis B vaccine at similar ages
Outcomes	Recurrent AOM episodes + AOM due to <i>S. pneumoniae</i> /non-vaccine type pneumococcal AOM AOM diagnosed by otoscopy (presence of abnormal tympanic membrane in terms of colour, position, or mobility, suggesting middle-ear effusion, plus at least one of the following symptoms or signs of acute infection (fever, earache, irritability, diarrhoea, vomiting, acute otorrhoea not caused by otitis externa, and other symptoms of respiratory infection)
Notes	This trial was part of a study including Kilpi 2003. Both Eskola 2001 and Kilpi 2003 used the same control group but a different index group, each with a different type of 7-valent pneumococcal conjugate vaccine

Risk of bias

Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B - Unclear

Fireman 2003

Methods	see Black 2000
Participants	see Black 2000
Interventions	see Black 2000
Outcomes	see Black 2000
Notes	

Risk of bias

Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B - Unclear

Kilpi 2003

Methods	Randomised controlled, double-blind trial	
Participants	Finland, multicentre trial of 1666 infants aged 2 months	
Interventions	7-valent pneumococcal conjugate vaccine (containing polysaccharides of serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F conjugated to the outer membrane protein complex of <i>N. meningitidis</i> serogroup B) at 2, 4, 6, and 12 months of age versus hepatitis B vaccine at similar ages. 22% of the children assigned to receive the 7-valent pneumococcal conjugate vaccine received 23-valent pneumococcal polysaccharide vaccination instead (containing saccharides of the serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F) at the age of 12 months	
Outcomes	See Eskola 2001	
Notes		
<i>Risk of bias</i>		
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Low risk	A - Adequate

Prymula 2006

Methods	Randomised controlled, double-blind trial	
Participants	Czech Republic/Slovakian multicentre trial of 4,968 infants aged between 6 weeks and 5 months	
Interventions	11-valent pneumococcal conjugate vaccine (containing polysaccharides of the serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F conjugated to protein D (surface lipoprotein of <i>H. influenzae</i>) at ages of ~ 2, 4, 5, and 12 to 15 months versus hepatitis A vaccines at similar ages	
Outcomes	Recurrent AOM episodes + AOM due to <i>S. pneumoniae</i> , (non) vaccine type pneumococcal AOM AOM diagnosed by either the visual appearance of the tympanic membrane (i.e. redness, bulging, loss of light reflex) or the presence of middle-ear effusion (as shown by simple or pneumatic otoscopy or by microscopy). The presence of at least two of the following signs or symptoms was required: earache, ear discharge, hearing loss, fever, lethargy, irritability, anorexia, vomiting or diarrhoea (these symptoms had to have started within the 14 days preceding the clinical diagnosis)	
Notes		
<i>Risk of bias</i>		
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B - Unclear

Van Kempen 2006

Methods	Randomised controlled, double-blind trial	
Participants	Belgian trial of 74 one- to seven-year-olds with at least two acute otitis media episodes in the year before study entry	
Interventions	7-valent pneumococcal conjugate vaccine (containing polysaccharides of serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F conjugated to the carrier protein CRM197) twice in 12- to 24-month-olds and once in 2- to -year-olds followed by 23-valent pneumococcal polysaccharide vaccination (containing polysaccharides of the serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F) respectively 6 and 7 months later versus hepatitis A vaccination in a similar time schedule	
Outcomes	AOM episodes diagnosed as the presence of an abnormal tympanic membrane on otoscopy (red, dull, or bulging), or otorrhoea and at least one of these signs or symptoms of acute infection: earache, acute otorrhoea, irritability, or fever (greater than 38.5°C rectally)	
Notes	Performed in parallel with the study of Veenhoven 2003 but analysed separately due to differences in study population	
<i>Risk of bias</i>		
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Low risk	A - Adequate

Veenhoven 2003

Methods	Randomised controlled, double-blind trial	
Participants	Dutch trial of 383 1- to 7-year-olds with at least two acute otitis media (AOM) episodes in the year before study entry	
Interventions	7-valent pneumococcal conjugate vaccine (containing polysaccharides of serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F conjugated to the carrier protein CRM197) twice in 12- to 24-month-olds and once in 2- to 7-year-olds followed by 23-valent pneumococcal polysaccharide vaccination (containing saccharides of the serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F) respectively 6 and 7 months later versus respectively hepatitis B or hepatitis A vaccination in a similar time schedule	
Outcomes	AOM episodes + AOM due to <i>Streptococcus pneumoniae</i> (non) vaccine type pneumococcal AOM AOM diagnosed as the presence of an abnormal tympanic membrane on otoscopy (red, dull, or bulging) , or otorrhoea and at least one of these signs or symptoms of acute infection: acute earache, new-onset otorrhoea, irritability, or fever greater than 38.5°C rectally or 38.0°C axillary	
Notes		
<i>Risk of bias</i>		
Bias	Authors' judgement	Support for judgement

Allocation concealment?	Low risk	A - Adequate
-------------------------	----------	--------------

AOM = acute otitis media

PCV = pneumococcal conjugate vaccine

ADDITIONAL TABLES

Table 1. Methodological quality of included studies.

Study	Randomised	R appropriate?	Double blinded	DB appropriate?	Withdrawals/ dropouts	Total score
Black (2000)	1	0	1	0	0	2
Eskola (2001)	1	0	1	0	0	2
Dagan (2001)	1	+1	1	+1	1	5
Fireman (2003)	1	0	1	0	0	2
Kilpi (2003)	1	+1	1	+1	0	4
Veenhoven (2003)	1	+1	1	+1	1	5
Van Kempen (2006)	1	+1	1	+1	1	5
Prymula (2006)	1	+1	1	0	1	4

R = Randomisation

DB = Double blinding

Table 2. The effect of pneumococcal conjugate vaccination on acute otitis media episodes

Pneumococcal conjugate vaccination administered in infancy		
	Episodes/person year	
	Index	Control
Intention-to-treat analysis		

Table 2. The effect of pneumococcal conjugate vaccination on acute otitis media episodes (Continued)

Firemean 2003	not reported	not reported	6% (4 to 8)
Eskola 2001	not reported	not reported	not reported
Kilpi 2003	not reported	not reported	not reported
Prymula 2006	not reported	not reported	not reported
Per-protocol analysis			
Firemean 2003	not reported	not reported	7% (4 to 9)
Eskola 2001	1.16	1.24	6% (-4 to 16)
Kilpi 2003	not reported	not reported	-1% (-12 to 10)
Prymula 2006	0.08	0.13	34% (21 to 44)
Pneumococcal conjugate vaccination administered at a later age			
	Episodes/person year		Relative reduction in risk (95% confidence interval)
	Index	Control	
Intention-to-treat analysis			
Dagan 2001	0.66	0.79	17% (-2 to 33)
Veenhoven 2003	not reported	not reported	-25% (-57 to 1)
Van Kempen 2006	not reported	not reported	not reported
Per-protocol analysis			
Dagan 2001	Not reported	Not reported	Not reported
Veenhoven 2003	1.1	0.83	-29% (-62 to -2)
Van Kempen 2006	0.78	0.67	-16% (-96 to 31)

Note: negative values represent an increase in the risk for AOM

Table 3. The effect of pneumococcal conjugate vaccination on pneumococcal acute otitis media

Pneumococcal conjugate vaccination administered in infancy			
	Relative reduction in risk (95% confidence interval); P-value		
	Pneumococcal AOM	Vaccine- type AOM	Non-vaccine-type AOM
Intention-to-treat analysis			
Black 2000	not reported	65%, P = 0.035	not reported
Eskola 2001	not reported	54% (41 to 64)	not reported
Kilpi 2003	not reported	not reported	not reported
Prymula 2006	not reported	not reported	not reported
Per-protocol analysis			
Black 2000	not reported	67%, P = 0.077	not reported
Eskola 2001	34% (21 to 45)	57% (44 to 67)	cross-reactives: 51% (27 to 67) others: -33% (-80 to 1)
Kilpi 2003	25% (11 to 37)	56% (44 to 66)	cross-reactives: -5% (-47 to 25) others: -27% (-70 to 6)
Prymula 2006	52% (37 to 63)	58% (41 to 69)	cross-reactives: 66% (22 to 85) others: 9% (-64 to 49)
Pneumococcal conjugate vaccination administered at a later age			
	Relative reduction in risk (95% confidence interval); P-value		
	Pneumococcal AOM	Vaccine- type AOM	non-vaccine-type AOM
Intention-to-treat analysis			
Dagan 2001	not reported	not reported	not reported
Veenhoven 2003	not reported	not reported	not reported
Van Kempen 2006	not reported	not reported	not reported
Per-protocol analysis			
Dagan 2001	not reported	not reported	not reported

Table 3. The effect of pneumococcal conjugate vaccination on pneumococcal acute otitis media (Continued)

Veenhoven 2003	34%, P = 0.22	52%, P = 0.21	21%, P = 0.44
Van Kempen 2006	not reported	not reported	not reported

Note: negative values represent an increase in the risk for AOM

Table 4. The effect of pneumococcal conjugate vaccination on recurrent acute otitis media

Pneumococcal conjugate vaccination administered in infancy	
	Relative reduction in risk (95% confidence interval)
Intention-to-treat analysis	
Black 2000	9% (4 to 14)
Eskola 2001	9% (-12 to 27)
Kilpi 2003	not reported
Prymula 2006	not reported
Per-protocol analysis	
Black 2000	9% (3 to 15)
Eskola 2001	16% (-6 to 35)
Kilpi 2003	not reported
Prymula 2006	56% (-2 to 81)
Pneumococcal conjugate vaccination administered at a later age	
	Relative reduction in risk (95% confidence interval)
Intention-to-treat analysis	
Dagan 2001	not reported
Veenhoven 2003	not reported
Van Kempen 2006	not reported
Per-protocol analysis	

Table 4. The effect of pneumococcal conjugate vaccination on recurrent acute otitis media (Continued)

Dagan 2001	not reported
Veenhoven 2003	not reported
Van Kempen 2006	not reported

WHAT'S NEW

Last assessed as up-to-date: 14 November 2007.

Date	Event	Description
9 September 2010	Amended	Contact details updated.

HISTORY

Protocol first published: Issue 2, 1999

Review first published: Issue 2, 2002

Date	Event	Description
29 April 2008	New citation required but conclusions have not changed	New review authors.
15 November 2007	New search has been performed	Searches conducted
28 April 2008	Amended	Converted to new review format
26 November 2003	New citation required and conclusions have changed	Substantive amendment
29 June 2003	New search has been performed	Searches conducted
19 August 2000	New search has been performed	Searches conducted

CONTRIBUTIONS OF AUTHORS

AJ, LS co-ordinated the review.

AJ, LS, EH were involved in data collection, quality assessment and analysis of data.

All review authors (AJ, LS, EH, RV, AS, RD) were involved in designing and writing the review and interpreting the data.

DECLARATIONS OF INTEREST

None known.

SOURCES OF SUPPORT

Internal sources

- Department of Pediatric Immunology and Infectious Diseases, UMC Utrecht, Wilhelmina Children's Hospital Utrecht, Netherlands.
- Julius Center for Health Sciences and Primary Care, UMC Utrecht, the Netherlands, Netherlands.
- Department of Pediatrics, Spaarne Hospital Haarlem, Netherlands.
- Department of Otorhinolaryngology, UMC Utrecht, Wilhelmina Children's Hospital Utrecht, Netherlands.

External sources

- No sources of support supplied

NOTES

The focus in research shifted from the use of PPVs to PCVs in children, and the role of PPVs in the prevention of AOM in children has merely been assessed following PCVs and not as a primary intervention anymore. Therefore, the focus of the current review has shifted from the effect of PPVs to the effect of PCVs on AOM. No further attention will be paid to the effect of PPVs, which was described in prior versions of this review ([Straetmans 2003](#)).

INDEX TERMS

Medical Subject Headings (MeSH)

Acute Disease; Otitis Media [microbiology; *prevention & control]; Pneumococcal Vaccines [*therapeutic use]; Randomized Controlled Trials as Topic; Vaccines, Conjugate [therapeutic use]

MeSH check words

Child; Child, Preschool; Humans; Infant